Glenmark Pharmaceuticals has been granted tentative approval by the US Food & Drug Administration (FDA) for its azelaic acid gel, a generic version of Bayer Healthcare’s Finacea topical gel. Glenmark will market this product upon receiving final approval of its azelaic acid gel ANDA.
The patent listed in the Orange Book for Finacea topical gel, which is used to treat mild to moderate rosacea (a skin condition marked by red eruptions, usually on the cheeks and nose), is scheduled to expire on November 18, 2018.
According to IMS Health sales data for the 12 month period ending December 2015, the Finacea market achieved annual sales of approximately $ 128 million.
The patent listed in the Orange Book for Finacea topical gel, which is used to treat mild to moderate rosacea (a skin condition marked by red eruptions, usually on the cheeks and nose), is scheduled to expire on November 18, 2018.
According to IMS Health sales data for the 12 month period ending December 2015, the Finacea market achieved annual sales of approximately $ 128 million.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%